INTRODUCTION: Quality of life studies indicate that overactive bladder (OAB) has a greater negative impact on everyday life than other serious conditions such as diabetes. The detrimental effect of OAB on female sexual health is more prominent than urinary incontinence. We know that tolterodine immediate release (IR) has a beneficial effect on urinary symptoms in OAB. AIM: To evaluate the impact of tolterodine IR on sexual function in patients with OAB. METHODS: A total of 30 sexually active women with OAB from 20 to 52 years were included. All patients filled out the International Consultation on Incontinence Questionnaire (ICIQ) and the Arizona Sexual Experience Scale (ASEX) before treatment with tolterodine IR and at the end of each month of treatment until 3 months. MAIN OUTCOME MEASURES: Expected outcomes were improvements in the ICIQ and ASEX total score. All ASEX items were expected to improve individually. These improvements indicate better sexual function after treatment. Results. The mean of the total ASEX score improved relative to baseline in the first (P<0.01), second (P<0.01), and third (P<0.01) follow-up. The mean of scores for sexual desire, arousal, vaginal lubrication, orgasm, and orgasm satisfaction improved significantly (P<0.01) with each follow-up. CONCLUSION: Tolterodine IR significantly improves sexual function of women with OAB. Improvement is seen in all domains of sexual function.
INTRODUCTION: Quality of life studies indicate that overactive bladder (OAB) has a greater negative impact on everyday life than other serious conditions such as diabetes. The detrimental effect of OAB on female sexual health is more prominent than urinary incontinence. We know that tolterodine immediate release (IR) has a beneficial effect on urinary symptoms in OAB. AIM: To evaluate the impact of tolterodine IR on sexual function in patients with OAB. METHODS: A total of 30 sexually active women with OAB from 20 to 52 years were included. All patients filled out the International Consultation on Incontinence Questionnaire (ICIQ) and the Arizona Sexual Experience Scale (ASEX) before treatment with tolterodine IR and at the end of each month of treatment until 3 months. MAIN OUTCOME MEASURES: Expected outcomes were improvements in the ICIQ and ASEX total score. All ASEX items were expected to improve individually. These improvements indicate better sexual function after treatment. Results. The mean of the total ASEX score improved relative to baseline in the first (P<0.01), second (P<0.01), and third (P<0.01) follow-up. The mean of scores for sexual desire, arousal, vaginal lubrication, orgasm, and orgasm satisfaction improved significantly (P<0.01) with each follow-up. CONCLUSION:Tolterodine IR significantly improves sexual function of women with OAB. Improvement is seen in all domains of sexual function.
Authors: Kyungtae Ko; Dae Yul Yang; Won Ki Lee; Sae Woong Kim; Du Geon Moon; Ki Hak Moon; Nam Cheol Park; Jong Kwan Park; Hwan Cheol Son; Sung Won Lee; Jae Seog Hyun; Kwangsung Park Journal: Korean J Urol Date: 2014-09-05
Authors: A Zachariou; C Mamoulakis; M Filiponi; F Dimitriadis; J Giannakis; S Skouros; P Tsounapi; A Takenaka; N Sofikitis Journal: BMC Urol Date: 2018-06-25 Impact factor: 2.264